#### Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: jzus@zju.edu.cn



# Association between *TaqIB* polymorphism of cholesteryl ester transfer protein and coronary artery disease in the Chinese population<sup>\*</sup>

Qi YU<sup>1</sup>, En-qi LIU<sup>1,2</sup>, Si-hai ZHAO<sup>†‡1,2</sup>, Ya-feng LI<sup>1</sup>, Yan-li WANG<sup>1</sup>, Yu-long CHEN<sup>1</sup>, Ke-na WEI<sup>1</sup>,

Bing-qiao HUANG<sup>1</sup>, Jian-lin FAN<sup>1,3</sup>, Peng-hui YANG<sup>1</sup>

(<sup>1</sup>Research Institute of Atherosclerotic Disease, Xi'an Jiaotong University School of Medicine, Shaanxi 710061, China) (<sup>2</sup>Laboratory Animal Center, Xi'an Jiaotong University School of Medicine, Shaanxi 710061, China)

(<sup>3</sup>Department of Molecular Pathology, Interdisciplinary Graduate School of Medicine and Engineering,

University of Yamanashi, Yamanashi 409-3898, Japan)

<sup>†</sup>E-mail: sihaizhao@mail.xjtu.edu.cn

Received Aug. 17, 2011; Revision accepted Oct. 28, 2011; Crosschecked Apr. 1, 2012

**Abstract:** Objective: To assess whether the *TaqIB* polymorphism of cholesteryl ester transfer protein (CETP) is associated with coronary artery disease (CAD) in Chinese population, we performed a meta-analysis in this paper. Methods: We searched PubMed, Embase, the Science Citation Index (SCI), the China Biological Medicine database (CBM), the China National Knowledge Infrastructure (CNKI), and the Wanfang database for relevant articles. Data were extracted, and pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Results: The literature search yielded 448 studies, in which 10 case-control studies including 1 694 cases and 1 456 controls matched the selection criteria. The combined B1 and B2 allele frequencies were 0.587 and 0.413, respectively. The pooled OR was 1.10 (95% CI, 0.89–1.34) for comparing the B1B1 or B1B2 carriers with B2B2 carriers, and was 1.27 (95% CI, 1.09–1.49) in the B1B1 carriers versus B2B2 or B1B2 carriers. Conclusions: In the present study, the *TaqIB* polymorphism of CETP was found to be associated with CAD in the Chinese population.

Key words:Cholesteryl ester transfer protein, Coronary artery disease, Polymorphism, Chinese populationdoi:10.1631/jzus.B1100264Document code: ACLC number: R541.4

# 1 Introduction

Coronary artery disease (CAD) is the leading cause of death, in both China and western countries (Libby, 1995). The cholesteryl ester transfer protein (CETP) plays an important role in cholesterol metabolism by exchanging the cholesteryl ester in high-density lipoprotein (HDL) for the triglycerides in very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), or chylomicrons (Groener *et al.*, 1986). The *CETP* gene contains 25 kilobases genomic DNA with 16 exons and 15 introns, and is located on chromosome 16 (Agellon *et al.*, 1990). Linkage analysis has shown that a marker locus linked to the CETP locus is involved in the determination of plasma concentrations of HDL cholesterol (HDL-C) and its associated lipoproteins (Bu *et al.*, 1994). Genetic variation at this locus has also been found to be associated with the variations of serum CETP activity and HDL-C concentration (Inazu *et al.*, 2000). Of the known genetic variants, the *TaqIB* polymorphism is common and has been

342

<sup>&</sup>lt;sup>‡</sup> Corresponding author

<sup>\*</sup> Project supported by the National Natural Science Foundation of China (Nos. 30900526 and 81070250), the Fundamental Research Funds for the Central Universities, and the China Postdoctoral Science Foundation (No. 20100471616)

<sup>©</sup> Zhejiang University and Springer-Verlag Berlin Heidelberg 2012

studied in detail. Several studies have shown an association of the CETP intron 1 TaqIB2 allele with a high HDL-C level and TaqIB1 with a low HDL-C level (Freeman et al., 1994; Dullaart et al., 1997; Kuivenhoven et al., 1998). A meta-analysis mainly including a Caucasian population found that the CETP TaqIB variant is firmly associated with HDL-C plasma levels, and as a result, with the risk of CAD (Boekholdt et al., 2005). However, whether the TaqIB polymorphism of CETP is associated with CAD remains unclear in studies mainly including Chinese subjects (Wu et al., 2001; Qin et al., 2004; Wang et al., 2004; Yan et al., 2004; Zhao et al., 2004; Zheng et al., 2004; Zhang Y. et al., 2003; Zhang G. et al., 2005; Wang, 2006; Li et al., 2007). Therefore, in this paper we performed a meta-analysis to assess the relationship between the TaqIB polymorphism of CETP and CAD in Chinese populations.

### 2 Materials and methods

# 2.1 Eligibility criteria

The inclusion criteria were: (1) un-related case-control studies; (2) complete data with genotype and allele frequencies (a genotype frequency of cases and controls is within Hardy-Weinberg equilibrium); (3) the publications that could be written in any language. Reports of duplicated studies were excluded by examining the author list, parent institution, sample size, and results.

#### 2.2 Information sources and searches

The PubMed, Embase, the Science Citation Index (SCI), the China Biological Medicine database (CBM), the China National Knowledge Infrastructure (CNKI), and the Wanfang database for relevant articles were searched. The keywords used in literature searching included: cholesteryl ester transfer protein, coronary artery disease, polymorphism, Chinese population, CETP and variants, and genetics.

## 2.3 Synthesis of results

Two authors (Drs. En-qi LIU and Si-hai ZHAO) independently screened titles and abstracts for potential eligibility and the full texts for final eligibility. We extracted the data independently from the included trials for quantitative analyses, and any disagreements were subsequently resolved by discussion. The measure of association used in this meta-analysis was the odds ratio (OR) with a 95% confidence interval (CI). The summary OR with the 95% CI was calculated with Revman 5.0 software using the fixed effect model (Review Manager Version 5.0 for Windows; the Cochrane Collaboration, Oxford, UK). A statistically significant result was assumed when the 95% CI did not include 1. Heterogeneity was explored using a chi-square test, and the quantity of heterogeneity was measured using the  $I^2$  statistics. Publication bias was assessed with funnel plot.

### 3 Results

## 3.1 Baseline characteristics of cases and controls

Fig. 1 shows the results of the study screen. The literature search yielded 448 studies, 10 of which matched the selection criteria. The combined sample size was 3150 (1694 cases; 1456 controls). There was unanimous agreement between the two authors (Drs. En-qi LIU and Si-hai ZHAO) regarding the selection of relevant articles. The baseline characteristics in the 10 included trials are summarized in Table 1.




Fig. 1 Analysis of the search results

#### 3.2 Primary meta-analysis

In this study, fixed effect model was used to analyze the ten included studies. The combined B1 and B2 allele frequencies were 0.587 and 0.413,

G( 1		Mean age	$n_{\rm M}/n_{\rm F}$	n <sub>G</sub>			Allele frequency	
Study	n <sub>s</sub>	(year)		B1B1	B1B2	B2B2	B1	B2
Li et al., 2007								
Case	176	61.7±12.5 <sup>a</sup>		82	73	21	0.588	0.412
Control	40	55.8±13.1		15	19	6	0.584	0.416
Qin et al., 2004								
Case	249	58.8±8.9	169/80	81	131	37	0.588	0.412
Control	167	55.1±9.0	89/78	49	97	21	0.584	0.416
Wang et al., 2004								
Case	128	62.9±5.6	82/46	50	66	12	0.648	0.352
Control	247	59.5±8.4	142/105	72	123	52	0.540	0.460
Wang, 2006								
Case	123	62.36 <sup>b</sup>	44/59	38	65	20	0.568	0.432
Control	103	48.17	84/39	33	51	19	0.573	0.427
Wu et al., 2001								
Case	149	20–82 <sup>c</sup>		45	79	25	0.595	0.405
Control	274	28-83		63	159	52	0.584	0.416
Yan et al., 2004								
Case	106	60±9	81/25	41	46	19	0.604	0.396
Control	64	57±11	31/33	19	34	11	0.564	0.437
Zhang G. et al., 2005								
Case	88	65±10		31	40	17	0.580	0.420
Control	94	54±18		32	50	12	0.606	0.394
Zhang Y. et al., 2003								
Case	234	59.5±8.2	135/99	76	126	32	0.595	0.405
Control	164	58.2±9.3	98/66	49	95	20	0.588	0.412
Zhao et al., 2004								
Case	238	61.3±9.2	224/217	95	105	38	0.620	0.380
Control	203		,	60	109	34	0.564	0.436
Zheng et al., 2004								
Case	203	59.3±8.7	137/77	66	114	23	0.606	0.394
Control	100	58.4±6.5	66/34	33	55	12	0.605	0.395

Table 1 Baseline characteristics of the cases and controls of included studies

 $n_{\rm S}$ : number of samples;  $n_{\rm M}/n_{\rm F}$ : male number/female number;  $n_{\rm G}$ : number of genotype. Mean age is expressed as mean±SD<sup>a</sup>, mean<sup>b</sup>, or range<sup>c</sup>

respectively. Overall, the pooled OR was 1.10 (95% CI, 0.89–1.34, P=0.38) when comparing B1B1 or B1B2 carriers with B2B2 carriers. Using OR as the measure of effect, the Cochran homogeneity test statistic yielded a P value of 0.34, and the heterogeneity was  $I^2=11\%$  (Fig. 2). The pooled OR was 1.27 (95% CI, 1.09–1.49, P=0.002) when comparing B1B1 carriers with B1B2 or B2B2 carriers. The Cochran homogeneity test statistic yielded a P value of 0.79, and the heterogeneity was  $I^2=0\%$  (Fig. 3).

### 3.3 Publication bias

We performed a funnel plot analysis to explore publication bias. All ten included studies for the comparison of B1B1 carriers with B1B2 or B2B2 carriers lied within the 95% CI line and the funnel plot did not show asymmetry. However, asymmetrical plot for comparison of B1B1 or B1B2 carriers with B2B2 carriers implied the existence of some publication bias (Fig. 4).

	Case	e	Contr	ol Odds ratio		Odds ratio	Odds ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Fixed. 95% C	I M-H. Fixed. 95% Cl		
Li <i>et al.</i> , 2007	155	176	34	40	3.7%	1.30 [0.49, 3.47]	_ <del></del>		
Qin <i>et al</i> ., 2004	212	249	146	167	14.5%	0.82 [0.46, 1.47]			
Wang et al., 2004	116	128	195	247	7.0%	2.58 [1.32, 5.03]	— <b>-</b>		
Wang, 2006	103	123	84	103	8.3%	1.16 [0.58, 2.32]	<del></del>		
Wu <i>et al</i> ., 2001	124	149	222	274	14.7%	1.16 [0.69, 1.96]	- <b>-</b>		
Yan <i>et al</i> ., 2004	87	106	53	64	6.6%	0.95 [0.42, 2.15]	<del></del>		
Zhang G. et al., 2005	71	88	82	94	8.6%	0.61 [0.27, 1.37]	<b>-</b> _		
Zhang Y. et al., 2003	202	234	144	164	12.9%	0.88 [0.48, 1.59]	<b>-</b> _		
Zhao <i>et al.</i> , 2004	200	238	169	203	16.3%	1.06 [0.64, 1.76]	_ <b>+</b> _		
Zheng et al., 2004	180	203	88	100	7.5%	1.07 [0.51, 2.24]	<b>_</b>		
Total (95% CI)		1694		1456	100.0%	1.10 [0.89, 1.34]	•		
Total events	1450		1217						
Heterogeneity: $\chi^2$ =10.13, <i>df</i> =9 ( <i>P</i> =0.34); <i>l</i> <sup>2</sup> =11%									
Test for overall effect: Z=0.88 (P=0.38) 0.1 0.2 0.5 1.0 2.0 5.0 10.0									
		2.50)					Decreased risk Increased risk		

Fig. 2 Odds ratios for coronary artery disease when comparing the B1B1 or B1B2 carries with B2B2 carriers Test for heterogeneity: chi-squared statistic with its degrees of freedom (*df*) and *P*-value; Inconsistency among results:  $l^2$ ; Test for overall effect: *Z* statistic with *P*-value




Fig. 3 Odds ratios for coronary artery disease when comparing the B1B1 carries with B1B2 or B2B2 carriers Test for heterogeneity: chi-squared statistic with its degrees of freedom (*df*) and *P*-value; Inconsistency among results:  $l^2$ ; Test for overall effect: *Z* statistic with *P*-value




Fig. 4 Funnel plot illustrating the included trials used in this meta-analysis

Dashed lines represent the 95% CI lines. SE: standard error, expressed as logOR; OR: odds ratio

#### 4 Discussion

As a modulator of HDL-C levels, CETP plays an important role in the molecular mechanism of human atherogenesis (Barter and Rye, 2001; Barter *et al.*, 2003). The *TaqIB* polymorphism in the *CETP* gene, located in intron 1, has played a prominent role in genetic association studies investigating the relation between CETP activity, lipids, and CAD risk. The CETP *TaqIB* variant was firmly associated with the risk of CAD in Caucasians (Boekholdt *et al.*, 2005). However, the association remains unclear in Chinese populations (Wu *et al.*, 2001; Zhang Y. *et al.*, 2003; Qin *et al.*, 2004; Wang *et al.*, 2004; Zhang G. *et al.*, 2004; Zhang Y. *et al.*, 2004; Zhang G. *et al.*, 2004; Zhang Y. *et al.*, 2004; Zhang G. *et al.*, 2004; Zhang Y. *et al.*, 2004; Zhang

2005; Wang, 2006; Li et al., 2007). In this meta-analysis, we observed that the TagIB polymorphism in the CETP gene exhibited a significant association with CAD in Chinese populations. The pooled OR was 1.27 (95% CI, 1.09-1.49) in the B1B1 carriers versus B2B2 or B1B2 carriers. The TaqIB genotype was still significantly associated with a higher risk of CAD in B1B1 individuals compared with B1B2 individuals and B2B2 individuals in Chinese populations. The B2 allele of the *TaqIB* polymorphism has been shown to be associated with higher HDL-C concentrations, and decreased CETP activity and CETP concentration (Kauma et al., 1996; Corbex et al., 2000; Ordovas et al., 2000). The TaqIB B1 allele has been marginally associated with the risk of developing CAD (Ordovas et al., 2000; Brousseau et al., 2002). Allele frequencies of the TaqIB polymorphism have been previously reported to differ by racial/ethnic groups (Cuchel et al., 2002; Liu et al., 2002). In this study, the allele frequencies of the TaqIB polymorphism in Chinese populations are similar to Caucasian populations reported by Tsai et al. (2008). In the Korean population, the B1B1 homozygote of the CETP TagIB polymorphism is associated with low HDL-C levels in females and non-smoking males, and may be an independent genetic risk factor of CAD (Park et al., 2003). It was also reported that the B2B2 genotype in CETP TaqIB polymorphism may act as a protective factor against atherosclerosis in Japanese (Goto et al., 2001). The results of this study also agree with these previous reports in different racial populations.

In conclusion, the *TaqIB* polymorphism of CETP was found to be associated with CAD in Chinese populations. The present study suggests that allele B1 might be a genetic risk factor for CAD in Chinese populations. These results may help predict future diseases, and allow for early diagnosis and prevention of CAD. The results also help to understand the mechanism of CAD and develop new drugs for CAD-related diseases.

It is important to mention that there were limitations in this meta-analysis. Though the main worldwide biomedical databases were searched to identify potential randomized control trails (RCTs), publication bias could not be avoided completely. In our study, an asymmetrical plot for comparison of B1B1 or B1B2 carriers with B2B2 carriers was found, implying the existence of some publication bias.

#### References

- Agellon, L.B., Quinet, E.M., Gillette, T.G., Drayna, D.T., Brown, M.L., Tall, A.R., 1990. Organization of the human cholesteryl ester transfer protein gene. *Biochemistry*, 29(6):1372-1376. [doi:10.1021/bi00458a004]
- Barter, P.J., Rye, K., 2001. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. *Curr. Opin. Lipidol.*, **12**(4):377-382. [doi:10.1097/00041433-200108 000-00002]
- Barter, P.J., Brewer, H.B., Chapman, M.J., Hennekens, C.H., Rader, D.J., Tall, A.R., 2003. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.*, 23(2): 160-167. [doi:10.1161/01.ATV.0000054658.91146.64]
- Boekholdt, S.M., Sacks, F.M., Jukema, J.W., Shepherd, J., Freeman, D.J., McMahon, A.D., Cambien, F., Nicaud, V., de Grooth, G.J., Talmud, P.J., *et al.*, 2005. Cholesteryl ester transfer protein *TaqIB* variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient metaanalysis of 13 677 subjects. *Circulation*, **111**(3):278-287. [doi:10.1161/01.CIR.0000153341.46271.40]
- Brousseau, M.E., O'Connor, J.J., Ordovas, J.M., Collins, D., Otvos, J.D., Massov, T., McNamara, J.R., Rubins, H.B., Robins, S.J., Schaefer, E.J., 2002. Cholesteryl ester transfer protein *TaqI* B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. *Arterioscler. Thromb. Vasc. Biol.*, **22**(7):1148-1154. [doi: 10.1161/01.ATV.0000024566.57589.2E]
- Bu, X., Warden, C.H., Xia, Y.R., de Meester, C., Puppione, D.L., Teruya, S., Lokensgard, B., Daneshmand, S., Brown, J., Gray, R.J., 1994. Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition: evidence for involvement of the apolipoprotein A-II and cholesteryl ester transfer protein loci. *Hum. Genet.*, 93(6):639-648. [doi:10.1007/BF00201563]
- Corbex, M., Poirier, O., Fumeron, F., Betoulle, D., Evans, A., Ruidavets, J.B., Arveiler, D., Luc, G., Tiret, L., Cambien, F., 2000. Extensive association analysis between the *CETP* gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. *Genet. Epidemiol.*, 19(1): 64-80. [doi:10.1002/1098-2272(200007)19:1<64::AID-GE PI5>3.0.CO;2-E]
- Cuchel, M., Wolfe, M.L., de Lemos, A.S., Rader, D.J., 2002. The frequency of the cholesteryl ester transfer protein *TaqI* B2 allele is lower in African Americans than in Caucasians. *Atherosclerosis*, **163**(1):169-174. [doi:10. 1016/S0021-9150(01)00769-9]
- Dullaart, R.P., Hoogenberg, K., Riemens, S.C., Groener, J.E., van Tol, A., Sluiter, W.J., Stulp, B.K., 1997. Cholesterol ester transfer protein gene polymorphism is a determinant of HDL cholesterol and of the lipoprotein response to a lipid-lowering diet in type 1 diabetes. *Diabetes*, 46(12): 2082-2087. [doi:10.2337/diabetes.46.12.2082]

- Freeman, D.J., Griffin, B.A., Holmes, A.P., Lindsay, G.M., Gaffney, D., Packard, C.J., Shepherd, J., 1994. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and invironmental factors. Association between the *Taq1B* RFLP in the CETP gene. *Arterioscler*. *Thromb. Vasc. Biol.*, 14(3):336-344. [doi:10.1161/01.ATV. 14.3.336]
- Goto, A., Sasai, K., Suzuki, S., Fukutomi, T., Ito, S., Matsushita, T., Okamoto, M., Suzuki, T., Itoh, M., Okumura-Noji, K., *et al.*, 2001. Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography. *Atherosclerosis*, **159**(1):153-163. [doi:10.1016/S0021-9150(01)00476-2]
- Groener, J.E., Pelton, R.W., Kostner, G.M., 1986. Improved estimation of cholesterol ester transfer/exchange activity in serum or plasma. *Clin. Chem.*, **32**(2):283-286.
- Inazu, A., Koizumi, J., Mabuchi, H., 2000. Cholesteryl ester transfer protein and atherosclerosis. *Curr. Opin. Lipidol.*, 11(4):389-396. [doi:10.1097/00041433-200008000-00008]
- Kauma, H., Savolainen, M.J., Heikkilä, R., Rantala, A.O., Lilja, M., Reunanen, A., Kesäniemi, Y.A., 1996. Sex difference in the regulation of plasma high density lipoprotein cholesterol by genetic and environmental factors. *Hum. Genet.*, 97(2):156-162. [doi:10.1007/BF02265258]
- Kuivenhoven, J.A., Jukema, J.W., Zwinderman, A.H., de Knijff, P., McPherson, R., Bruschke, A.V., Lie, K.I., Kastelein, J.J., 1998. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. *New Engl. J. Med.*, **338**(2):86-93. [doi:10.1056/NEJM199801083380203]
- Li, J., Deng, B., Lv, L., Zhao, M., Zheng, L., 2007. The association of the cholesterol ester transfer protein *TaqIB* polymorphism with the plasma lipids in patients with acute coronary syndrome. *J. Clin. Cardiol.*, **23**(9):663-665 (in Chinese).
- Libby, P., 1995. Molecular bases of the acute coronary syndromes. *Circulation*, **91**(11):2844-2850.
- Liu, S., Schmitz, C., Stampfer, M.J., Sacks, F., Hennekens, C.H., Lindpaintner, K., Ridker, P.M., 2002. A prospective study of *TaqIB* polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. *Atherosclerosis*, **161**(2): 469-474. [doi:10.1016/S0021-9150(01)00673-6]
- Ordovas, J.M., Cupples, L.A., Corella, D., Otvos, J.D., Osgood, D., Martinez, A., Lahoz, C., Coltell, O., Wilson, P.W., Schaefer, E.J., 2000. Association of cholesteryl ester transfer protein-*TaqIB* polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. *Arterioscler. Thromb. Vasc. Biol.*, **20**(5):1323-1329. [doi:10.1161/01.ATV.20.5.1323]
- Park, K.W., Choi, J.H., Kim, H.K., Oh, S., Chae, I.H., Kim, H.S., Oh, B.H., Lee, M.M., Park, Y.B., Choi, Y.S., 2003.

The association of cholesteryl ester transfer protein polymorphism with high-density lipoprotein cholesterol and coronary artery disease in Koreans. *Clin. Genet.*, **63**(1):31-38. [doi:10.1034/j.1399-0004.2003.630105.x]

- Qin, Q., Zhao, B., Geng, J., Li, Y., Cui, R., Mao, Y., Hui, R., 2004. The association of the lipoprotein lipase S447X and cholesteryl ester transfer protein *TaqIB* polymorphism with coronary heart disease. *Chin. J. Cardiol.*, **32**(6): 522-525 (in Chinese).
- Tsai, M.Y., Johnson, C., Kao, W.H., Sharrett, A.R., Arends, V.L., Kronmal, R., Jenny, N.S., Jacobs, D.R., Arnett, D., O'Leary, D., *et al.*, 2008. Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis*, **200**(2):359-367. [doi:10.1016/j.atherosclerosis.2007.12.038]
- Wang, W., Zhou, X., Liu, F., Hu, H., Han, D., 2004. Association of the *TaqIB* polymorphism and D442G mutation of cholesteryl ester transfer protein gene with coronary heart disease. *Chin. J. Cardiol.*, **32**(11):981-985 (in Chinese).
- Wang, Y., 2006. The Effects of Cholesterol Ester Transfer Protein Polymorphism on Plasma Lipids Level and Its Relationship with Type 2 Diabetes Mellitus and Coronary Heart Disease. MS Thesis, Peking Union Medical College, Beijing, China (in Chinese).
- Wu, J.H., Lee, Y.T., Hsu, H.C., Hsieh, L.L., 2001. Influence of *CETP* gene variation on plasma lipid levels and coronary heart disease: a survey in Taiwan. *Atherosclerosis*, 159(2):451-458. [doi:10.1016/S0021-9150(01)00524-X]
- Yan, S., Zhu, Y., Cheng, S., Song, Y., Yan, X., Zhu, W., 2004. Relationship between coronary heart disease and *TaqIB* & Msp I polymorphisms of cholesteryl ester transfer protein gene in Han nationality. *Chin. J. Lab. Med.*, 27(10):671-675 (in Chinese).
- Zhang, G., Jiang, Z., Sun, B., Lu, Y., Wen, Q., Zhuang, W., Wang, F., 2005. Relationship of *TaqIB* polymorphism in the cholesteryl ester transfer protein gene to coronary artery disease. *Chin. J. Arterioscler.*, **13**(1):88-90 (in Chinese).
- Zhang, Y., Geng, J., Qin, Q., Mao, Y., Cui, R., 2003. The effects of *TaqIB* polymorphism of cholesteryl ester transfer protein on coronary heart disease. *Tianjin Med. J.*, **31**(12):758-760 (in Chinese).
- Zhao, S., Li, H., Xiao, Z., Nie, Z., 2004. The effects of *TaqIB* polymorphism of cholesteryl ester transfer protein on plasma lipoprotein level. *Chin. J. Cardiol.*, **32**(9):816-818 (in Chinese).
- Zheng, K.Q., Zhang, S.Z., He, Y., Zhang, L., Zhang, K.L., Huang, D.J., Sun, Y., 2004. Association between cholesteryl ester transfer protein gene polymorphisms and variations in lipid levels in patients with coronary heart disease. *Chin. Med. J. (Engl.)*, **117**(9):1288-1292 (in Chinese).